TR199901669T2 - Erkeklerdeki ereksiyon probleminin tedavisi için gerekli dozaj sekilleri ve metod. - Google Patents

Erkeklerdeki ereksiyon probleminin tedavisi için gerekli dozaj sekilleri ve metod.

Info

Publication number
TR199901669T2
TR199901669T2 TR1999/01669T TR9901669T TR199901669T2 TR 199901669 T2 TR199901669 T2 TR 199901669T2 TR 1999/01669 T TR1999/01669 T TR 1999/01669T TR 9901669 T TR9901669 T TR 9901669T TR 199901669 T2 TR199901669 T2 TR 199901669T2
Authority
TR
Turkey
Prior art keywords
men
treatment
dosage forms
erectile dysfunction
required dosage
Prior art date
Application number
TR1999/01669T
Other languages
English (en)
Inventor
Stewart Johnson Edward
Clarke Anthony
Richard Green David
Original Assignee
R. P. Scherer Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R. P. Scherer Limited filed Critical R. P. Scherer Limited
Publication of TR199901669T2 publication Critical patent/TR199901669T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Dopamin agonist, testosteron ve bunun karisimlarindan seçilen aktif içerik ve bir tasiyicidan olusan, agizdan kullanim için bir ilaç kompozisyonu olup, bu kompozisyon, erkeklerde ereksiyon probleminin tedavisi için bir ilaç üretimine yönelik olarak agiz boslugunda aktif içerigin dagilmasi hizli dagilan bir dozaj seklindedir.
TR1999/01669T 1997-01-17 1998-01-16 Erkeklerdeki ereksiyon probleminin tedavisi için gerekli dozaj sekilleri ve metod. TR199901669T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9700878.3A GB9700878D0 (en) 1997-01-17 1997-01-17 Dosage forms and method for ameliorating male erectile dysfunction

Publications (1)

Publication Number Publication Date
TR199901669T2 true TR199901669T2 (tr) 2000-07-21

Family

ID=10806104

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/01669T TR199901669T2 (tr) 1997-01-17 1998-01-16 Erkeklerdeki ereksiyon probleminin tedavisi için gerekli dozaj sekilleri ve metod.

Country Status (27)

Country Link
US (2) US6342246B2 (tr)
EP (1) EP0954314B1 (tr)
JP (1) JP2000513736A (tr)
KR (1) KR100416768B1 (tr)
CN (1) CN1243440A (tr)
AT (1) ATE211385T1 (tr)
AU (1) AU717337B2 (tr)
BG (1) BG103570A (tr)
BR (1) BR9808888A (tr)
CA (1) CA2276758A1 (tr)
DE (1) DE69803360T2 (tr)
DK (1) DK0954314T3 (tr)
EE (1) EE03805B1 (tr)
ES (1) ES2167061T3 (tr)
GB (1) GB9700878D0 (tr)
HU (1) HUP0001089A3 (tr)
IL (1) IL130714A0 (tr)
NO (1) NO993520L (tr)
NZ (1) NZ336436A (tr)
PL (1) PL334656A1 (tr)
PT (1) PT954314E (tr)
RU (1) RU2204413C2 (tr)
SK (1) SK283301B6 (tr)
TR (1) TR199901669T2 (tr)
UA (1) UA62954C2 (tr)
WO (1) WO1998031368A1 (tr)
YU (1) YU33099A (tr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
GB9813278D0 (en) * 1998-06-20 1998-08-19 Medical Res Council Male contraceptive
JP2000178204A (ja) * 1998-10-05 2000-06-27 Eisai Co Ltd ホスフォジエステラ―ゼ阻害剤を含有する口腔内速崩壊性錠剤
CA2251255A1 (en) * 1998-10-20 2000-04-20 Mcgill University The use of dopaminergic agents in the management of sexual dysfunction
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6506765B2 (en) 2000-04-07 2003-01-14 Tap Pharmaceutical Products, Inc. Apomorphine derivatives and methods for their use
SE0002934D0 (sv) 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
MXPA03001858A (es) * 2000-08-30 2004-05-21 Unimed Pharmaceuticals Inc Metodo para el tratamiento de la disfuncion erectil e incremento en el libido del hombre.
US20020103105A1 (en) * 2000-11-22 2002-08-01 Brioni Jorge D. Use of selective dopamine D4 receptor agonists for treating sexual dysfunction
US6960589B2 (en) 2001-03-09 2005-11-01 Abbott Laboratories Benzimidazoles that are useful in treating sexual dysfunction
US7022728B2 (en) 2001-03-09 2006-04-04 Abbott Laboratories Benzimidazoles that are useful in treating male sexual dysfunction
US20020169166A1 (en) * 2001-03-09 2002-11-14 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
US20030008878A1 (en) * 2001-03-09 2003-01-09 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
FR2834894B1 (fr) * 2002-01-21 2004-02-27 Servier Lab Composition pharmaceutique orodispersible de piribedil
FR2834897B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible de testosterone
WO2003080030A1 (en) * 2002-03-26 2003-10-02 Bernard Charles Sherman Stable tablets comprising pergolide mesylate
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US20040156894A1 (en) * 2003-02-07 2004-08-12 Grother Leon Paul Use of edible acids in fast-dispersing pharmaceutical solid dosage forms
US20050137265A1 (en) * 2003-03-31 2005-06-23 Haley Eugene T. Rapidly dissolving metoclopramide solid oral dosage and method thereof
DE602004031512D1 (de) * 2003-03-31 2011-04-07 Titan Pharmaceuticals Inc Polymeres implantat zur verzögerten freisetzung von dopamin antagonisten
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20050089502A1 (en) * 2003-08-21 2005-04-28 Todd Schansberg Effervescent delivery system
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
AU2006236564B2 (en) 2005-04-15 2011-02-17 Tolmar, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
BRPI0617294B8 (pt) 2005-10-12 2021-05-25 Besins Healthcare Lu Sarl composição farmacêutica em gel hidroalcóolico e uso de testosterona
EP2043613A1 (en) * 2006-07-14 2009-04-08 Fmc Corporation Solid form
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US8861813B2 (en) * 2008-03-13 2014-10-14 Mallinckrodt Llc Multi-function, foot-activated controller for imaging system
US20100168119A1 (en) * 2008-11-05 2010-07-01 Pharmorx, Inc. Compositions and methods for minimizing or reducing agonist-induced desensitization
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US8545879B2 (en) 2009-08-31 2013-10-01 Wilmington Pharmaceuticals, Llc Fast disintegrating compositions of meloxicam
PL2493457T3 (pl) 2009-10-30 2018-01-31 Ix Biopharma Ltd Szybko rozpuszczalna stała postać dawkowana
CN101797260B (zh) * 2009-12-23 2011-09-21 济南圣泉唐和唐生物科技有限公司 L-阿拉伯糖在制备用于治疗阴茎勃起障碍药物中的用途
JP6061859B2 (ja) * 2010-10-08 2017-01-18 アール．ピー． シェーラー テクノロジーズ エルエルシー デンプンを使用する経口ワクチン速溶性剤型
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
NZ703341A (en) 2012-06-05 2016-11-25 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
EP2950799B1 (en) 2013-01-30 2019-12-04 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
EP3544614A4 (en) 2016-11-28 2020-08-05 Lipocine Inc. ORAL TESTOSTERONE UNDECANOATE THERAPY

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928566A (en) * 1970-08-14 1975-12-23 Du Pont Lyophilized biological products
US4098802A (en) * 1975-02-18 1978-07-04 Akzona Incorporated Oral pharmaceutical preparation having androgenic activity
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
US5135752A (en) * 1988-10-14 1992-08-04 Zetachron, Inc. Buccal dosage form
HUT75616A (en) * 1992-03-17 1997-05-28 Pfizer Method for prooucing porous delivery devices
SG46962A1 (en) * 1994-01-27 1998-03-20 Janssen Pharmaceutica Inc Rapidly dissolving oral dosage form
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
ATE312609T1 (de) * 1994-04-22 2005-12-15 Pentech Pharmaceuticals Inc Sublinguale zusammensetzung enthaltend apomorphine zur diagnose der funktionellen impotenz
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions

Also Published As

Publication number Publication date
SK97299A3 (en) 2000-11-07
ES2167061T3 (es) 2002-05-01
AU5671098A (en) 1998-08-07
US20020156056A1 (en) 2002-10-24
DE69803360D1 (de) 2002-02-28
WO1998031368A1 (en) 1998-07-23
SK283301B6 (sk) 2003-05-02
KR20000070264A (ko) 2000-11-25
US20010018069A1 (en) 2001-08-30
BR9808888A (pt) 2000-10-03
BG103570A (bg) 2000-04-28
PL334656A1 (en) 2000-03-13
UA62954C2 (en) 2004-01-15
YU33099A (sh) 2002-06-19
KR100416768B1 (ko) 2004-01-31
JP2000513736A (ja) 2000-10-17
EP0954314A1 (en) 1999-11-10
RU2204413C2 (ru) 2003-05-20
EE03805B1 (et) 2002-08-15
CN1243440A (zh) 2000-02-02
DK0954314T3 (da) 2002-02-18
EE9900288A (et) 2000-02-15
IL130714A0 (en) 2000-06-01
AU717337B2 (en) 2000-03-23
NZ336436A (en) 2000-07-28
US6342246B2 (en) 2002-01-29
ATE211385T1 (de) 2002-01-15
EP0954314B1 (en) 2002-01-02
NO993520D0 (no) 1999-07-16
DE69803360T2 (de) 2002-10-10
GB9700878D0 (en) 1997-03-05
PT954314E (pt) 2002-06-28
HUP0001089A2 (hu) 2000-11-28
NO993520L (no) 1999-09-16
HUP0001089A3 (en) 2001-03-28
CA2276758A1 (en) 1998-07-23

Similar Documents

Publication Publication Date Title
TR199901669T2 (tr) Erkeklerdeki ereksiyon probleminin tedavisi için gerekli dozaj sekilleri ve metod.
NZ511201A (en) Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby
GEP20043203B (en) EP4 Receptor Selective Agonists in the Treatment of Osteoporosis
ATE329897T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
MY129356A (en) Electrospun pharmaceutical compositions
RS50407B (sr) Oralne formulacije opijatnog agonista otporne na mehaničke,termičke i/ili hemijske promene fizičkih osobina doznog oblika
ATE253892T1 (de) Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
ATE387430T1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
ES2194989T3 (es) Composicion adminstrada por via oral, que comprende una toxina de zonula occludens y un agente que tiene una actividad biologica, y su utilizacion.
DE60024414T2 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
DE60019334D1 (de) Antivirale arznei
HUP0100705A2 (hu) Hatóanyag-kombinációk alkalmazása, valamint ilyen kombinációkat tartalmazó gyógyszerkészítmények és készletek impotencia kezelésére
NO20004419L (no) Ny anvendelse
PT941085E (pt) Dispositivo para administracao electricamente assistida de agentes como a lidocaina e a epinefrina
DE60103865D1 (de) Arzneizubereitungen und deren herstellungsverfahren
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
ATE303774T1 (de) Vorrichtung und verfahren zur behandlung von erektionsstörungen
FR12C0064I2 (fr) Compositions pharmaceutiques injectables d'un derive d'anthracenedione avec action anti-tumorale
PL348202A1 (en) Pharmaceutically active composition and dispensing device
HRP20000781B1 (en) Effervescent preparations
SE0202365D0 (sv) New formulation and use thereof
BR0211323A (pt) Combinação de ingredientes ativos, uso de uma combinação de ingredientes ativos e método de terapia farmacológica de dependência de nicotina
AR021502A1 (es) Uso de derivados de azabicicloalcanos n-sustituidos para el tratamiento de enfermedades del sistema central nervioso
ATE240097T1 (de) Pharmaceutische zusammensetzung enthaltend (+)- ephedrin und einen h1 rezeptor antagonisten
ATE386524T1 (de) Wässrige lösungen von moxaverin zur behandlung der erektilen dysfunktion